- Home
- PIM vs ATOS Comparison
PIM vs ATOS Comparison
Compare PIM & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- ATOS
- Stock Information
- Founded
- PIM 1988
- ATOS 2009
- Country
- PIM United States
- ATOS United States
- Employees
- PIM N/A
- ATOS N/A
- Industry
- PIM Finance Companies
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- PIM Finance
- ATOS Health Care
- Exchange
- PIM Nasdaq
- ATOS Nasdaq
- Market Cap
- PIM 162.3M
- ATOS 174.8M
- IPO Year
- PIM N/A
- ATOS 2012
- Fundamental
- Price
- PIM $3.33
- ATOS $1.45
- Analyst Decision
- PIM
- ATOS Strong Buy
- Analyst Count
- PIM 0
- ATOS 3
- Target Price
- PIM N/A
- ATOS $6.25
- AVG Volume (30 Days)
- PIM 57.5K
- ATOS 507.3K
- Earning Date
- PIM 01-01-0001
- ATOS 11-12-2024
- Dividend Yield
- PIM 8.28%
- ATOS N/A
- EPS Growth
- PIM N/A
- ATOS N/A
- EPS
- PIM 0.05
- ATOS N/A
- Revenue
- PIM N/A
- ATOS N/A
- Revenue This Year
- PIM N/A
- ATOS N/A
- Revenue Next Year
- PIM N/A
- ATOS N/A
- P/E Ratio
- PIM $63.80
- ATOS N/A
- Revenue Growth
- PIM N/A
- ATOS N/A
- 52 Week Low
- PIM $2.90
- ATOS $0.62
- 52 Week High
- PIM $3.28
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- PIM 40.02
- ATOS 52.72
- Support Level
- PIM $3.34
- ATOS $1.34
- Resistance Level
- PIM $3.44
- ATOS $1.48
- Average True Range (ATR)
- PIM 0.03
- ATOS 0.06
- MACD
- PIM -0.01
- ATOS -0.00
- Stochastic Oscillator
- PIM 8.33
- ATOS 45.83
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.